BLUEJET Share Price Performance
₹0
-918.40 (-100.00%)
Price ₹0
Fair Value₹821.68
Share Pricen/a
Narrative Update • May 21
Blue Jet Healthcare Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
BLUEJET Community Narratives
AN
Fair Value
·Fair Value ₹821.68 45.6% undervalued intrinsic discount
Aging Populations And Chronic Disease Will Feed Indian Pharma Outsourcing
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value ₹330 35.3% overvalued intrinsic discount
Escalating Regulatory And Supply Risks Will Weaken Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value ₹499.17 10.5% undervalued intrinsic discount
Analysts Lower Blue Jet Healthcare Valuation as Revenue Growth Projections Moderate Amid Company Updates
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Aging Populations And Chronic Disease Will Feed Indian Pharma Outsourcing
Blue Jet Healthcare looks set up to ride a long wave of demand as drugmakers lean more on Indian partners and new treatments for long-term health conditions need more specialized ingredients. The upside comes from big new factory capacity and deeper control of its supply chain, but the story hinges on winning and keeping a small number of major customers while managing rising competition and tighter regulation.Read more
AN
₹821.68
45.6% undervalued intrinsic discount
Fair Value
Revenue
35.42% p.a.
Profit Margin
14.47%
Future PE
53.19x
Price in 2029
₹1.17k
Escalating Regulatory And Supply Risks Will Weaken Outlook
Key Takeaways Margin and earnings growth are threatened by global regulatory pressures, environmental compliance costs, and increased supply chain risks linked to emerging market dependencies. Heavy reliance on a concentrated customer base and lagging technological adaptation heighten the risk of revenue volatility and competitive disadvantages.Read more
AN
₹330
35.3% overvalued intrinsic discount
Fair Value
Revenue
5.98% p.a.
Profit Margin
22.62%
Future PE
28.48x
Price in 2029
₹469.32
Analysts Lower Blue Jet Healthcare Valuation as Revenue Growth Projections Moderate Amid Company Updates
Key Takeaways Expansion into high-margin specialties and backward integration enhances Blue Jet's cost efficiency, product portfolio, and margin stability. Strong global pharma trends and long-term client relationships support robust, sustained demand and recurring earnings growth.Read more
AN
₹499.17
10.5% undervalued intrinsic discount
Fair Value
Revenue
17.6% p.a.
Profit Margin
19.49%
Future PE
36.6x
Price in 2029
₹709.91
Trending Discussion
Recently Updated Narratives
AN
BLUEJET: Vizag Expansion Will Support Future Upside As New Facility Scales
Fair Value: ₹821.68 45.6% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BLUEJET: Vizag Capex Plans Will Sustain Concerns Over Rich Earnings Multiple
Fair Value: ₹330 35.3% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BLUEJET: Higher Future P/E Assumptions Will Support Dividend Appeal
Fair Value: ₹499.17 10.5% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Blue Jet Healthcare Limited Key Details
About BLUEJET
- Founded
- 1968
- Employees
- 196
- CEO
- WebsiteView website
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
